To reach the next value inflection
LicenseRx asset brief
Aryl Hydantoin Heterocycle Compounds that Target the Androgen Receptor for Prostate Cancer Treatment
Probability of Success
24% · grade C · Medium data confidence
Model PoS 24% (grade C, medium data confidence). Strongest signals: Data maturity, IP position. Biggest drag: Translational evidence.
Data maturity (22%)
54
Preclinical; limited public evidence of validation.
IP position (16%)
72
Patent filed/pending -- prosecution ongoing.
Modality feasibility (14%)
82
Small molecule -- well-trodden regulatory and CMC path.
Indication pull (14%)
78
Oncology, Cardiometabolic -- active buyer appetite.
Competitive whitespace (12%)
60
Crowded oncology field.
Translational evidence (12%)
46
No translational evidence keywords in the public summary -- lab-stage claim.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →